In this clinical update, we look at recent advances in two clinical-stage gene-editing programmes. Editas Medicine's sickle cell disease candidate...

In this clinical update, we look at four ongoing clinical trials involving a gene-edited therapeutic candidate for the treatment of solid cancers.

Researchers from Italy’s Ospedale San Raffaele Scientific Institute, in collaboration with Intellia Therapeutics, have used CRISPR to introduce...

This week's update features Iovance Biotherapeutics' new cancer immunotherapy candidate IOV-4001 that was recently cleared for clinical trial...

This week's update includes news about two gene-edited therapies for cancer. Allogene Therapeutics' ALLO-316 has been granted Fast Track Designation...

This week’s IND update looks at FT536, a gene-edited natural killer cell therapy developed by Fate Therapeutics for the treatment of multiple solid...

In our first clinical update of 2022, we look at three new IND approvals for gene-edited therapies for life-threatening E. coli infections,...

In 2021, we've seen positive clinical data for the first ever in vivo CRISPR medicines, base editors are heading for the clinic, and CRISPR therapies...